Exscientia Said Sanofi Is Adding A New Discovery Stage Program Into The Current Collaboration; Exscientia Is Eligible For Up To $45M In Upfront And Preclinical Milestone Payments And Over $300M Is Milestone Payments
Portfolio Pulse from Benzinga Newsdesk
Exscientia announced that Sanofi is expanding their collaboration by adding a new discovery stage program. Exscientia is eligible to receive up to $45M in upfront and preclinical milestone payments, and potentially over $300M in additional milestone payments.
December 21, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Exscientia stands to gain up to $45M in upfront and preclinical milestone payments, plus over $300M in additional milestones from the expanded collaboration with Sanofi.
The news of the expanded collaboration with Sanofi and the potential for significant milestone payments is likely to be viewed positively by investors, potentially increasing Exscientia's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
NEUTRAL IMPACT
Sanofi is enhancing its partnership with Exscientia by adding a new discovery stage program, which could lead to future innovative treatments.
While the news is positive for Sanofi's research and development efforts, the financial impact is less significant relative to Sanofi's overall financial position, thus the short term stock impact may be neutral.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70